Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient
Keywords:Beta-thalassemia, Glyt1, Medicinal chemistry, Pet, Schizophrenia, Transporter
AbstractGlycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical companies and academic institutions primarily as a potential new approach to treat schizophrenia, a severe and chronic mental illness. More recently, preclinical results have suggested that this approach could also have therapeutic potential for CNS disorders beyond schizophrenia as well as for non-CNS indications. Over the past 17 years, Roche has been a key player in the GlyT1 field with the discovery and development of bitopertin, the most advanced GlyT1 inhibitor to date and the only one which completed Phase III clinical studies for schizophrenia. In this article, we relate the eventful journey of the discovery and development of bitopertin, from project initiation in 2001 to its evaluation today in patients suffering from beta-thalassemia, a monogenic hereditary haematological disorder.
How to Cite
E. Pinard, E. Borroni, A. Koerner, D. Umbricht, D. Alberati, Chimia 2018, 72, 477, DOI: 10.2533/chimia.2018.477.
Copyright (c) 2018 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.